Skip to main content
Mark Stein, MD, Oncology, New York, NY

MarkSteinMD

Oncology New York, NY

Genitourinary Oncology, Hematologic Oncology

Medical Oncologist at Columbia University Medical Center

Dr. Stein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Stein's full profile

Already have an account?

  • Office

    161 Fort Washington Ave
    Fl 9
    New York, NY 10032
    Phone+1 212-305-5874
    Fax+1 212-305-6762

Summary

  • Dr. Mark Stein is an oncologist in New York, NY and is affiliated with Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center/New York–Presbyterian Hospital. He received his medical degree from New York Medical College and has been in practice 19 years. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for cancer

Education & Training

  • New York Medical College
    New York Medical CollegeClass of 1998

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NJ State Medical License
    NJ State Medical License 2004 - 2025
  • NY State Medical License
    NY State Medical License 1999 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Study Sheds Light on Diabetes Drug for Prostate Cancer
    Study Sheds Light on Diabetes Drug for Prostate CancerNovember 8th, 2023
  • Common Diabetes Drug Metformin Really Can Fight Certain Cancers
    Common Diabetes Drug Metformin Really Can Fight Certain CancersNovember 10th, 2023
  • Can Metformin Delay Progression of Prostate Cancer? Study Provides Insights
    Can Metformin Delay Progression of Prostate Cancer? Study Provides InsightsNovember 11th, 2023

Professional Memberships